Graham Roberts1, Catriona Hurley, Gideon Lack. 1. Pediatric Allergy, Asthma, and Immunology, Imperial College School of Medicine at St Mary's, London, United Kingdom.
Abstract
BACKGROUND: Health-related quality of life (HRQOL) questionnaires currently being used to evaluate allergic disease are organ-specific. They therefore fail to take account of the systemic aspects of allergic disease. OBJECTIVE: To develop and validate a pediatric HRQOL questionnaire for allergic disease (Pediatric Allergic Disease Quality of Life Questionnaire, PADQLQ) that encapsulates problems related to the eyes, ears, nose, lungs, skin, emotions, and everyday activities. METHODS: In the development phase, 77 subjects (6 to 16 years of age), with seasonal or perennial allergic problems, were asked how much they were bothered by each different area of HRQOL impairment. The highest scoring areas were used to construct the PADQLQ. In the validation phase of the study, 36 subjects (8 to 16 years of age) with seasonal allergic rhinoconjunctivitis, seasonal allergic asthma, and/or cutaneous manifestations of grass pollen allergy were assessed before and during the pollen season. RESULTS: The PADQLQ contains 26 questions. In addition to standard symptoms (eg, rhinitis), it incorporates multiorgan symptoms that are usually overlooked (eg, hearing problems). The PADQLQ demonstrated good cross-sectional and longitudinal validity, showing a high degree of correlation with symptom scores and quality of life as measured by a visual analogue scale and two-organ specific questionnaires. The PADQLQ showed good within-subject reliability and a small minimal important difference (0.33; 95% CI, 0.11 to 0.54 on a 7-point scale). CONCLUSIONS: The PADQLQ has good cross-sectional and longitudinal validity, making it a potentially useful outcome measure in the evaluation of systemic treatments such as antihistamine medications and immunotherapy in children with multisystem allergic disease.
BACKGROUND: Health-related quality of life (HRQOL) questionnaires currently being used to evaluate allergic disease are organ-specific. They therefore fail to take account of the systemic aspects of allergic disease. OBJECTIVE: To develop and validate a pediatric HRQOL questionnaire for allergic disease (Pediatric Allergic Disease Quality of Life Questionnaire, PADQLQ) that encapsulates problems related to the eyes, ears, nose, lungs, skin, emotions, and everyday activities. METHODS: In the development phase, 77 subjects (6 to 16 years of age), with seasonal or perennial allergic problems, were asked how much they were bothered by each different area of HRQOL impairment. The highest scoring areas were used to construct the PADQLQ. In the validation phase of the study, 36 subjects (8 to 16 years of age) with seasonal allergic rhinoconjunctivitis, seasonal allergic asthma, and/or cutaneous manifestations of grass pollen allergy were assessed before and during the pollen season. RESULTS: The PADQLQ contains 26 questions. In addition to standard symptoms (eg, rhinitis), it incorporates multiorgan symptoms that are usually overlooked (eg, hearing problems). The PADQLQ demonstrated good cross-sectional and longitudinal validity, showing a high degree of correlation with symptom scores and quality of life as measured by a visual analogue scale and two-organ specific questionnaires. The PADQLQ showed good within-subject reliability and a small minimal important difference (0.33; 95% CI, 0.11 to 0.54 on a 7-point scale). CONCLUSIONS: The PADQLQ has good cross-sectional and longitudinal validity, making it a potentially useful outcome measure in the evaluation of systemic treatments such as antihistamine medications and immunotherapy in children with multisystem allergic disease.
Authors: Melinda Butsch Kovacic; Jocelyn M Biagini Myers; Mark Lindsey; Tia Patterson; Sharon Sauter; Mark B Ericksen; Patrick Ryan; Amal Assa'ad; Michelle Lierl; Thomas Fischer; Carolyn Kercsmar; Karen McDowell; Anne W Lucky; Anita P Sheth; Andrew D Hershey; Richard M Ruddy; Marc E Rothenberg; Gurjit K Khurana Hershey Journal: Pediatr Allergy Immunol Pulmonol Date: 2012-06 Impact factor: 1.349
Authors: Mirella De Civita; Dean Regier; Abul H Alamgir; Aslam H Anis; Mark J Fitzgerald; Carlo A Marra Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981
Authors: Kam Lun Hon; Yan Min Bao; Kate C Chan; Kin Wai Chau; Rong-Shan Chen; Kun Tat Gary Cheok; Wa Keung Chiu; Li Deng; Chun-Hui He; Kin Mui Ieong; Jeng Sum C Kung; Ping Lam; Shu Yan David Lam; Qun Ui Lee; So Lun Lee; Ting Fan Leung; Theresa N H Leung; Lei Shi; Ka Ka Siu; Wei-Ping Tan; Maggie Haitian Wang; Tak Wai Wong; Bao-Jing Wu; Ada Y F Yip; Yue-Jie Zheng; Daniel K Ng Journal: World J Pediatr Date: 2018-07-25 Impact factor: 2.764
Authors: Alexandra F Santos; Luis Miguel Borrego; Giuseppina Rotiroti; Glenis Scadding; Graham Roberts Journal: Clin Transl Allergy Date: 2015-01-24 Impact factor: 5.871
Authors: Darío Antolín-Amérigo; Luis Manso; Marco Caminati; Belén de la Hoz Caballer; Inmaculada Cerecedo; Alfonso Muriel; Mercedes Rodríguez-Rodríguez; José Barbarroja-Escudero; María José Sánchez-González; Beatriz Huertas-Barbudo; Melchor Alvarez-Mon Journal: Clin Mol Allergy Date: 2016-02-17